Chronic Myeloid Leukemia: A Minimalistic View of Post-Therapeutic Monitoring
- 28 February 2002
- journal article
- review article
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 4 (1) , 1-10
- https://doi.org/10.1016/s1525-1578(10)60675-7
Abstract
No abstract availableKeywords
This publication has 84 references indexed in Scilit:
- Commentary: Minimal residual disease: How low do we go?Molecular Diagnosis, 2001
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Quality assurance in RT-PCR-based BCR/ABL diagnostics – results of an interlaboratory test and a standardization approachLeukemia, 2000
- Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCRLeukemia, 1999
- Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a ‘real time’ quantitative RT-PCR assayLeukemia, 1999
- Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real‐time quantitative RT‐PCRBritish Journal of Haematology, 1998
- Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.Journal of Clinical Investigation, 1994
- Improved results with PCR for chronic myeloid leukaemiaThe Lancet, 1990
- False-positive results with PCR to detect leukaemia-specific transcriptThe Lancet, 1990
- Induction of Chronic Myelogenous Leukemia in Mice by the P210
bcr/abl
Gene of the Philadelphia ChromosomeScience, 1990